Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,550 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Carcinoma (NSCLC) Clear all
Completed Phase 2 Interventional

Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00004924
View directory record Official record
Conditions
Lung Cancer
Interventions
irinotecan hydrochloride, paclitaxel
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
2
States / cities
New Haven, Connecticut • Torrington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT00050960
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bexarotene with carboplatin and paclitaxel, carboplatin and paclitaxel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
121
States / cities
Montgomery, Alabama • Tucson, Arizona • Concord, California + 102 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Acceptability of Less Harmful Alternatives to Cigarettes

NCT00957424
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration
Behavioral · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

NCT00511576
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma, Prostate Cancer, Prostatic Cancer, Gastric Cancer, Stomach Cancer
Interventions
MGCD0103 & Docetaxel
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00003317
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy, surgery
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
16
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 6, 2026, 11:14 PM EDT
Completed No phase listed Observational

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

NCT05250817
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated No phase listed Observational

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

NCT01141218
View directory record Official record
Conditions
Lung Cancer
Interventions
internet-based protocol and physician referral
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 4 Interventional Results available

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions
Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT00003497
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 1 Interventional

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

NCT00461110
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
BMS-663513
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 1 Interventional

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
Interventions
BLU-701, osimertinib, carboplatin, pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 6, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01639508
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125
View directory record Official record
Conditions
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions
AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
14
States / cities
Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

NCT05570825
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, CXCR1/2 Inhibitor SX-682, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Active, not recruiting No phase listed Observational

MYLUNG Consortium Study Protocol 2

NCT05644808
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Daphne, Alabama • Denver, Colorado • Pensacola, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Terminated Phase 2 Interventional Results available

Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

NCT01029925
View directory record Official record
Conditions
Metastatic Breast Cancer, Lung Cancer
Interventions
Dichloroacetate (DCA)
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00004225
View directory record Official record
Conditions
Lung Cancer
Interventions
Ad5CMV-p53 gene, radiation therapy
Biological · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 6, 2026, 11:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249
View directory record Official record
Conditions
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
Interventions
JDQ443, trametinib, Ribociclib, cetuximab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

NCT00040638
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
TLK286
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Tucson, Arizona • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00073385
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pivanex, Docetaxel
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
5
States / cities
La Verne, California • New Orleans, Louisiana • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2005 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

NCT01281124
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 6, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT07659782
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
VS-7375
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Tamarac, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 1Phase 2 Interventional

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

NCT00073723
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 6, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Trial of Poor Performance Status Patients (ToPPS)

NCT00892710
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 6, 2026, 11:14 PM EDT